Add like
Add dislike
Add to saved papers

Noninvasive biodegradable nanoparticles-in-nanofibers single-dose ocular insert: in vitro, ex vivo and in vivo evaluation.

Nanomedicine 2018 December 14
AIM: This study involves, for the first time, the development of mucoadhesive biodegradable polymeric-multilayered nanoparticles-in-nanofibers (NPs-in-NFs) matrix as an innovative single-dose noninvasive ocular-insert that could substitute conventional ocular dosage-forms.

MATERIALS & METHODS: Azithromycin-loaded poly(lactic-co-glycolic acid) copolymer/pluronic NPs were developed then incorporated into electrospun polyvinylpyrrolidone NFs, and tested for their efficient treatment of ocular bacterial infection.

RESULTS: Release and permeation studies proved the ability of the insert to control drug release over 10 days.

CONCLUSION: The incorporation of NPs into NFs achieved several other benefits like increasing ocular residence and contact time with conjunctival tissue, accurate dose delivery, sustaining drug release with constant rate, reducing frequency of administration, improving bioavailability along with decreasing incidence of visual and systemic side effects.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

Related Resources

For the best experience, use the Read mobile app

Mobile app image

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.

By using this service, you agree to our terms of use and privacy policy.

Your Privacy Choices Toggle icon

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app